targeting nuclear factor-kappa b to overcome resistance to chemotherapy.
Clicks: 222
ID: 156295
2013
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Popular Article
30.0
/100
221 views
19 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Intrinsic or acquired resistance to chemotherapeutic agents is a common phenomenon and a major challenge to the treatment of cancer patients, especially those with progressive disease. Chemoresistance is defined by a complex network of factors including multi-drug resistance proteins, reduced cellular uptake of the drug, enhanced DNA repair, intracellular drug inactivation and evasion of apoptosis. Preclinical models have demonstrated activation of the NF-κB pathway by several chemotherapy drugs, including platinum based agents, anthracyclines and taxanes. NF-κB is a key transcription factor, playing a role in the development and progression of cancer as well as chemoresistance through the activation of anti-apoptotic genes. Consequently, NF-κB has emerged as a promising anticancer target. Here, we describe the role of NF-κB in the cancer cell and in resistance to chemotherapeutic agents, particularly cisplatin. Additionally, the potential benefits and disadvantages of targeting NF-κB signalling by pharmacological intervention will be addressed.
| Reference Key |
egodwin2013frontierstargeting
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Peter eGodwin;Anne-Marie eBaird;Susan eHeavey;Martin eBarr;Kenneth eO'Byrne;Kathy Ann Gately |
| Journal | international journal of heat and technology |
| Year | 2013 |
| DOI |
10.3389/fonc.2013.00120
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.